Published: August 24, 2026
Brand name drugs Generic drugs
In a year marked by record-high negotiation volumes and agreements reached, the pan-Canadian Pharmaceutical Alliance (pCPA) also reached new heights when it comes to savings for public drug plans. Estimates for the 2025–26 fiscal year include:
- $4.4 billion in savings on brand-name drugs
- $940 million in savings on generic drugs
- $5.4 billion in total savings for public drug plans
- More than $34 billion in cumulative savings since 2010
Savings generated through pCPA negotiations and generic pricing initiatives help federal, provincial, and territorial governments make the most of finite healthcare resources. This supports public drug plans to remain sustainable and offer wide public coverage for effective treatments.
We look forward to sharing more record highlights in our 2025–26 impact report, coming this fall. In the meantime, you can explore our performance dashboard to learn more about our negotiations, timelines, and other real-time metrics.